Cargando…

Prospective analysis of circulating metabolites and breast cancer in EPIC

BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was establ...

Descripción completa

Detalles Bibliográficos
Autores principales: His, Mathilde, Viallon, Vivian, Dossus, Laure, Gicquiau, Audrey, Achaintre, David, Scalbert, Augustin, Ferrari, Pietro, Romieu, Isabelle, Onland-Moret, N. Charlotte, Weiderpass, Elisabete, Dahm, Christina C., Overvad, Kim, Olsen, Anja, Tjønneland, Anne, Fournier, Agnès, Rothwell, Joseph A., Severi, Gianluca, Kühn, Tilman, Fortner, Renée T., Boeing, Heiner, Trichopoulou, Antonia, Karakatsani, Anna, Martimianaki, Georgia, Masala, Giovanna, Sieri, Sabina, Tumino, Rosario, Vineis, Paolo, Panico, Salvatore, van Gils, Carla H., Nøst, Therese H., Sandanger, Torkjel M., Skeie, Guri, Quirós, J. Ramón, Agudo, Antonio, Sánchez, Maria-Jose, Amiano, Pilar, Huerta, José María, Ardanaz, Eva, Schmidt, Julie A., Travis, Ruth C., Riboli, Elio, Tsilidis, Konstantinos K., Christakoudi, Sofia, Gunter, Marc J., Rinaldi, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757362/
https://www.ncbi.nlm.nih.gov/pubmed/31547832
http://dx.doi.org/10.1186/s12916-019-1408-4
_version_ 1783453561190875136
author His, Mathilde
Viallon, Vivian
Dossus, Laure
Gicquiau, Audrey
Achaintre, David
Scalbert, Augustin
Ferrari, Pietro
Romieu, Isabelle
Onland-Moret, N. Charlotte
Weiderpass, Elisabete
Dahm, Christina C.
Overvad, Kim
Olsen, Anja
Tjønneland, Anne
Fournier, Agnès
Rothwell, Joseph A.
Severi, Gianluca
Kühn, Tilman
Fortner, Renée T.
Boeing, Heiner
Trichopoulou, Antonia
Karakatsani, Anna
Martimianaki, Georgia
Masala, Giovanna
Sieri, Sabina
Tumino, Rosario
Vineis, Paolo
Panico, Salvatore
van Gils, Carla H.
Nøst, Therese H.
Sandanger, Torkjel M.
Skeie, Guri
Quirós, J. Ramón
Agudo, Antonio
Sánchez, Maria-Jose
Amiano, Pilar
Huerta, José María
Ardanaz, Eva
Schmidt, Julie A.
Travis, Ruth C.
Riboli, Elio
Tsilidis, Konstantinos K.
Christakoudi, Sofia
Gunter, Marc J.
Rinaldi, Sabina
author_facet His, Mathilde
Viallon, Vivian
Dossus, Laure
Gicquiau, Audrey
Achaintre, David
Scalbert, Augustin
Ferrari, Pietro
Romieu, Isabelle
Onland-Moret, N. Charlotte
Weiderpass, Elisabete
Dahm, Christina C.
Overvad, Kim
Olsen, Anja
Tjønneland, Anne
Fournier, Agnès
Rothwell, Joseph A.
Severi, Gianluca
Kühn, Tilman
Fortner, Renée T.
Boeing, Heiner
Trichopoulou, Antonia
Karakatsani, Anna
Martimianaki, Georgia
Masala, Giovanna
Sieri, Sabina
Tumino, Rosario
Vineis, Paolo
Panico, Salvatore
van Gils, Carla H.
Nøst, Therese H.
Sandanger, Torkjel M.
Skeie, Guri
Quirós, J. Ramón
Agudo, Antonio
Sánchez, Maria-Jose
Amiano, Pilar
Huerta, José María
Ardanaz, Eva
Schmidt, Julie A.
Travis, Ruth C.
Riboli, Elio
Tsilidis, Konstantinos K.
Christakoudi, Sofia
Gunter, Marc J.
Rinaldi, Sabina
author_sort His, Mathilde
collection PubMed
description BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. RESULTS: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. CONCLUSIONS: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1408-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6757362
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67573622019-09-30 Prospective analysis of circulating metabolites and breast cancer in EPIC His, Mathilde Viallon, Vivian Dossus, Laure Gicquiau, Audrey Achaintre, David Scalbert, Augustin Ferrari, Pietro Romieu, Isabelle Onland-Moret, N. Charlotte Weiderpass, Elisabete Dahm, Christina C. Overvad, Kim Olsen, Anja Tjønneland, Anne Fournier, Agnès Rothwell, Joseph A. Severi, Gianluca Kühn, Tilman Fortner, Renée T. Boeing, Heiner Trichopoulou, Antonia Karakatsani, Anna Martimianaki, Georgia Masala, Giovanna Sieri, Sabina Tumino, Rosario Vineis, Paolo Panico, Salvatore van Gils, Carla H. Nøst, Therese H. Sandanger, Torkjel M. Skeie, Guri Quirós, J. Ramón Agudo, Antonio Sánchez, Maria-Jose Amiano, Pilar Huerta, José María Ardanaz, Eva Schmidt, Julie A. Travis, Ruth C. Riboli, Elio Tsilidis, Konstantinos K. Christakoudi, Sofia Gunter, Marc J. Rinaldi, Sabina BMC Med Research Article BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. RESULTS: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. CONCLUSIONS: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1408-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-24 /pmc/articles/PMC6757362/ /pubmed/31547832 http://dx.doi.org/10.1186/s12916-019-1408-4 Text en © The Author(s). 2019 The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the WHO, its Board of Directors, or the countries they represent. Open Access This article is licensed under the terms of the Creative Commons Attribution 3.0 IGO License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the WHO, provide a link to the Creative Commons licence and indicate if changes were made. The use of the WHO’s name, and the use of the WHO’s logo, shall be subject to a separate written licence agreement between the WHO and the user and is not authorized as part of this CC-IGO licence. Note that the link provided above includes additional terms and conditions of the licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/3.0/igo/.
spellingShingle Research Article
His, Mathilde
Viallon, Vivian
Dossus, Laure
Gicquiau, Audrey
Achaintre, David
Scalbert, Augustin
Ferrari, Pietro
Romieu, Isabelle
Onland-Moret, N. Charlotte
Weiderpass, Elisabete
Dahm, Christina C.
Overvad, Kim
Olsen, Anja
Tjønneland, Anne
Fournier, Agnès
Rothwell, Joseph A.
Severi, Gianluca
Kühn, Tilman
Fortner, Renée T.
Boeing, Heiner
Trichopoulou, Antonia
Karakatsani, Anna
Martimianaki, Georgia
Masala, Giovanna
Sieri, Sabina
Tumino, Rosario
Vineis, Paolo
Panico, Salvatore
van Gils, Carla H.
Nøst, Therese H.
Sandanger, Torkjel M.
Skeie, Guri
Quirós, J. Ramón
Agudo, Antonio
Sánchez, Maria-Jose
Amiano, Pilar
Huerta, José María
Ardanaz, Eva
Schmidt, Julie A.
Travis, Ruth C.
Riboli, Elio
Tsilidis, Konstantinos K.
Christakoudi, Sofia
Gunter, Marc J.
Rinaldi, Sabina
Prospective analysis of circulating metabolites and breast cancer in EPIC
title Prospective analysis of circulating metabolites and breast cancer in EPIC
title_full Prospective analysis of circulating metabolites and breast cancer in EPIC
title_fullStr Prospective analysis of circulating metabolites and breast cancer in EPIC
title_full_unstemmed Prospective analysis of circulating metabolites and breast cancer in EPIC
title_short Prospective analysis of circulating metabolites and breast cancer in EPIC
title_sort prospective analysis of circulating metabolites and breast cancer in epic
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757362/
https://www.ncbi.nlm.nih.gov/pubmed/31547832
http://dx.doi.org/10.1186/s12916-019-1408-4
work_keys_str_mv AT hismathilde prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT viallonvivian prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT dossuslaure prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT gicquiauaudrey prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT achaintredavid prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT scalbertaugustin prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT ferraripietro prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT romieuisabelle prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT onlandmoretncharlotte prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT weiderpasselisabete prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT dahmchristinac prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT overvadkim prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT olsenanja prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT tjønnelandanne prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT fournieragnes prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT rothwelljosepha prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT severigianluca prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT kuhntilman prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT fortnerreneet prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT boeingheiner prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT trichopoulouantonia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT karakatsanianna prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT martimianakigeorgia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT masalagiovanna prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT sierisabina prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT tuminorosario prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT vineispaolo prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT panicosalvatore prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT vangilscarlah prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT nøstthereseh prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT sandangertorkjelm prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT skeieguri prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT quirosjramon prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT agudoantonio prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT sanchezmariajose prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT amianopilar prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT huertajosemaria prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT ardanazeva prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT schmidtjuliea prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT travisruthc prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT ribolielio prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT tsilidiskonstantinosk prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT christakoudisofia prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT guntermarcj prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic
AT rinaldisabina prospectiveanalysisofcirculatingmetabolitesandbreastcancerinepic